Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease

By Michael Bartl, MD, Mohammed Dakna, Douglas Galasko, Samantha J. Hutten, Tatiana Foroud, Marian Quan, Ken Marek, MD, Andrew Siderowf, Jonas Franz, MD, Claudia Trenkwalder and Brit Mollenhauer , MD
Published October 7, 2021
View Published Article

Output Details

Published October 7, 2021

Description
Several pathophysiological processes are involved in Parkinson’s disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer’s Disease, in a PD cohort. Except for αSyn, the additional biomarkers did not differentiate PD and HC, and none showed longitudinal differences, but most markers predict cognitive decline in PD during follow-up.
Identifier (DOI)
10.1371/journal.pone.0257372
Tags
  • Biomarkers
  • CSF (Cerebral Spinal Fluid)
  • Original Research
  • Parkinson's disease
Program
Parkinson's Progression Markers Initiative

Meet the Authors

Related Research

Characterizing Parkinson’s Disease Clinical and Biomarker Interactions in REM Sleep Behavior Disorder

a-syn SAA positivity, DaT positivity, and hyposmia are highly associated with each other. MDS Prodromal PD Probability scores may be useful predictors of near-term progression, and thus as a stratification factor in clinical research study design

View Article

Soluble Immune Factor Profiles in Blood and CSF Associated with LRRK2 Mutations and Parkinson’s Disease

This preprint explores immune factors in Parkinson's disease linked to LRRK2 mutations. Serum showed elevated SDF-1 alpha and TNF-RII levels in LRRK2 carriers, while CSF had reduced immune markers. PD patients displayed reduced CSF inflammation.

View Article

Combining biomarkers for prognostic modelling of Parkinson’s disease

Parkinson's disease progression varies among patients. Predicting progression accurately is crucial for clinical trial selection. Blood biomarkers like serum NfL, along with genetic factors (GBA, APOE) can enhance prediction beyond age and phenotype.

View Article
View More Outputs